Although commonly expressed human melanoma-associated antigens r g d by CD8+ cytolytic T cells have been described, little is known about CD4+ T-cell recognition of melanoma-aated antigens. Epstein-Barr virustransformed B cells were used to present antigens derived from whole cell lysates of autologous and allogeneic melanomas for recognition by melanoma-specific CD4+ T-cell lines and clones cultured from tumor-infiltrating lymphocytes. HLA-DRrestricted antigens were detected in the lysates on the basis of specific release of cytokines from the responding T cells. Antigen sharing was demonstrated in the majority of melanomas tested, as well as in cultured normal melanocytes, but not in other normal tissues or nonmelanoma tumors. T-cell clones manifested a single recognition pattern, suggesting the presence of an immunodominant epitope. This epitope was identified as a product of the tyrosinase gene, which has also been shown to encode class I-restricted epitopes recognized by CD8+ T cells from melanoma patients. Identification of commonly expressed tumor-associated protein molecules containing epitopes presented by both class I and class H major histocompatibility molecules may provide optimal reagents for cancer immunization strategies.
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Commonly expressed melanoma-associated antigens can be recognized by CD8+ cytotoxic T lymphocytes (CTLs) derived from melanoma patients. In short-term lysis assays, CTLs grown from in vitro sensitized peripheral blood lymphocytes (PBLs) or lymph node lymphocytes or from lymphocytes infiltrating metastatic melanoma lesions have been shown to recognize autologous and major histocompatibility complex (MHC) class I-compatible allogeneic melanomas but not HLA-matched nonmelanoma tumors, lymphoblasts, or cultured fibroblasts (1, 2) . Similar recognition patterns have been observed by measuring cytokine secretion from tumor infiltrating lymphocytes (TILs) cocultivated with autologous or HLA-matched allogeneic tumor stimulators (3) . Expression of shared melanoma antigens even in tumors of discrepant HLA phenotypes has been shown by genetically modifying these tumors to express the HLA-A2.1 molecule: HLA-A2-restricted melanoma-specific CTLs lysed the majority of gene-modified melanomas tested, but not HLA-A2+ nonmelanoma tumors or normal tissues (4, 5) . Recently, melanoma-specific HLA-A2-restricted CTL clones have been shown to recognize cultured normal melanocytes as well as their malignant counterparts, suggesting that shared melanoma antigens may be lineage specific (6) . The multiplicity of melanoma-associated antigens present within isolated melanoma lesions, and even within individual melanoma cells, has been suggested on the cellular level (7, 8 ) and confirmed on the peptide level (9, 10) . Five MHC class I-restricted melanoma-associated antigens have been molecularly defined (11) (12) (13) (14) (15) (16) , encoding only a subset of these commonly expressed antigens. Therapeutic vaccination strategies are evolving based on these CD8-recognized epitopes.
While animal models of malignant and viral diseases have shown the importance of CD8+ T cells in the effector phase of the immune response, the CD4+ helper arm has been shown to mediate critical priming and effector functions as well. We therefore addressed the issue of whether shared melanoma antigens are recognized by melanoma-specific CD4+ T cells. To facilitate screening procedures for shared CD4-recognized melanoma determinants, we devised an assay system which uses an autologous or MHC class IImatched allogeneic Epstein-Barr virus (EBV)-transformed B-cell line to present antigens derived from tumor cell lysates; reactivity in CD4+ T cells was measured by cytokine secretion (17) . By using a single professional antigenpresenting cell (APC) to present putative tumor-specific antigens from various sources for T-cell recognition, rather than measuring direct T-cell-tumor cell interactions, we circumvented issues of hidden HLA genotype discrepancies (18) (19) (20) as well as potential antigen-processing defects which have been documented in some human tumors (21) . We report here the identification of a commonly expressed MHC class II-restricted melanoma-associated antigen recognized by CD4+ T cells from TILs.
MATERIALS AND METHODS
Lymphocyte Cultures and Clones. TILs were cultured from enzymatically digested single-cell suspensions of solid metastatic melanoma lesions as described (22) , in the presence of recombinant interleukin 2 (IL-2, 6000 units/ml; Chiron), and were used in bioassays after 45-70 days. CD4+ and CD8+ TIL subsets were purified from bulk cultures by positive panning (23 (27) . EBV-B cells were pulsed with lysates of transfected COS-7 cells for recognition by T cells. The tyrosinase gene was isolated from a cDNA library from the cultured melanoma line 1290A-mel, and its identity was confirmed by partial DNA sequencing, which gave a sequence identical to that published by Bouchard et al. (28) . The tyrosinase-(1-3) gene, also isolated from the 1290A-mel library, lacks the exons 4 and 5 and encodes a truncated product. The gene encoding tyrosinase-related protein (gp75) was isolated by screening a cDNA library from 501-mel with a probe constructed on the basis of the published gene sequence (29) . RESULTS A variety of allogeneic tumors and normal tissues were screened for the presence of antigens recognized by CD41 TIL 1088. In a representative experiment (Fig. 2) Fig. 3 . These results suggested that the antigens recognized by CD4+ TIL 1088 might be specific for the melanocytic lineage.
We previously identified two other melanoma patients whose CD4+ TILs recognized lysates of autologous melanoma cells presented by autologous or HLA-matched EBV-B cells (17) . These TILs appeared to be MHC class II-restricted and to recognize antigens unique to autologous melanoma cells, since they failed to react with 15 allogeneic melanomas including 1088-mel or with normal cells including cultured melanocytes. These results suggest the existence of multiple class II-restricted melanoma determinants which are differentially and specifically recognized by CD4+ T cells from these three patients.
TILs cultured in bulk under the conditions described have been shown to be oligoclonal, but not monoclonal, cell populations (30) (31) (32) . To determine whether multiple shared antigens were being recognized by CD4+ TIL 1088, CD4+
T-cell clones were raised from these TILs and assayed for target recognition. Four (34) , allelic or mutational diversity of the tyrosinase gene affecting peptide structure, or the sensitivity threshold of our assay system. However, we cannot exclude the possibility that a by-product of a chemical reaction catalyzed by tyrosinase, rather than the tyrosinase molecule itself, may be the source of specific antigen for CD4+ TIL 1088. Though formally possible, this latter mechanism is unlikely, since none of the known reaction products of tyrosinase are peptidic in nature.
Tyrosinase regulates the conversion of tyrosine to the complex melanin pigment polymer. Tyrosinase gene expression is tissue specific, normally restricted to cells of melanocytic lineage. The recognition ofits protein product by T cells infiltrating a metastatic melanoma lesion suggests a breach of immunologic tolerance. This breach has presumably occurred within the tumor milieu and perhaps has been facilitated by ex vivo culture conditions. Such immunoreactivity, while potentially toxic to normal tissues, might be manipulated to therapeutic advantage in the setting of cancer treatment. Proteins such as tyrosinase, containing epitopes recognized by both CD4+ and CD8+ T cells, may prove to be Proc. Nadl. Acad. Sci. USA 91 (1994) 9465 tGenes were expressed in the plasmid vector pcDNA3 except for the tyrosinase-related gp75 gene, which was in pCEV27. tNet secretion is defined in footnote t to Table 1 . Values for TIL with EBV-B ranged from 10 to 237 pg/ml. optimal immunogens in vaccination strategies which will simultaneously recruit the helper and cytotoxic arms of the anti-tumor immune response. The importance of CD4+ T cells in the primning and effector phases ofthe anti-tumor immune response has been shown in animal models (35) (36) (37) (38) . Although experimental immunization strategies for patients with melanoma and other cancers currently emphasize shared class I-restricted tumor antigens recognized by CD8+ T cells, immunization against both class I-and class II-restricted epitopes may increase the effectiveness of these approaches. Previous reports suggesting the presence of shared MHC class II-restricted melanoma antigens have measured direct T-cell-tumor cell interactions and were thus limited by the extensive polymorphism of human class II molecules and reagent availability (39) (40) (41) (42) . However, as demonstrated here, a bioassay which utilizes one APC for multiple sources of antigen will permit rapid screening and detection of shared CD4-recognized tumor antigens. This detection system, coupled with chromatographic protein separation techniques to isolate different components of antigen-containing whole cell lysates, may be ideal for cloning additional relevant genes.
